COX6 Antibody

What is COX6C and what is its primary function in cellular metabolism?

COX6C (Cytochrome c oxidase subunit 6C) is one of the nuclear-encoded polypeptide chains of cytochrome c oxidase, which serves as the terminal oxidase in the mitochondrial respiratory chain . This enzyme is composed of 13 different subunits and catalyzes the electron transfer from reduced cytochrome c to oxygen . COX6C is specifically located in the mitochondrion inner membrane as a single-pass membrane protein . Functionally, it is integral to the electron transport chain and cellular respiration, playing a crucial role in ATP production through oxidative phosphorylation.

The protein has a calculated molecular weight of approximately 9 kDa and consists of 75 amino acids . Understanding COX6C is important as it represents a key component in cellular energy metabolism, and alterations in its expression or function can have significant implications for mitochondrial function and cellular homeostasis.

What applications are COX6C antibodies most commonly used for in research?

COX6C antibodies are utilized across multiple experimental applications, with the most common being:

For Western blot applications, COX6C antibodies typically detect a band at approximately 9 kDa, though some antibodies may detect bands at different molecular weights (e.g., 32 kDa) depending on the specific epitope and potential post-translational modifications . When using these antibodies, researchers should verify reactivity with their species of interest, as most commercial antibodies show reactivity with human, mouse, and rat samples .

How should COX6C antibodies be stored and handled to maintain optimal activity?

For optimal preservation of antibody activity, COX6C antibodies should be stored at -20°C, where they typically remain stable for up to one year . Most commercial preparations are supplied in liquid form in PBS containing 50% glycerol, 0.5% BSA, and 0.02% sodium azide as a preservative .

When working with these antibodies:

• Avoid repeated freeze-thaw cycles which can compromise antibody function

• For the 11429-2-AP antibody specifically, aliquoting is unnecessary for -20°C storage

• Allow antibodies to reach room temperature before opening the vial

• Briefly centrifuge before use to collect contents at the bottom of the tube

• When diluting, use fresh, sterile buffers and avoid contamination

• 20µl sizes often contain 0.1% BSA for additional stability

Proper storage and handling not only extends the shelf-life of the antibody but also ensures consistent experimental results across multiple studies.

What are the optimal antigen retrieval methods for COX6C immunohistochemistry?

The optimal antigen retrieval methods for COX6C immunohistochemistry depend on the specific tissue type and fixation method employed. Based on available data:

For human pancreatic cancer tissues, the suggested antigen retrieval involves TE buffer at pH 9.0 . Alternatively, citrate buffer at pH 6.0 can be used if TE buffer produces suboptimal results . The specific protocol typically involves:

• Deparaffinization and rehydration of tissue sections

• Heat-induced epitope retrieval (HIER) using TE buffer (pH 9.0) or citrate buffer (pH 6.0)

• Cooling to room temperature gradually

• Blocking of endogenous peroxidases with hydrogen peroxide

• Protein blocking to reduce background staining

• Incubation with primary COX6C antibody at dilutions ranging from 1:20 to 1:200

For lung adenocarcinoma (LUAD) tissues, similar antigen retrieval methods have been employed successfully in tissue microarray (TMA) analysis . Researchers should note that optimization may be required for each specific tissue type and antibody combination, and preliminary experiments to determine the most effective antigen retrieval method are advised.

How can researchers troubleshoot non-specific binding when using COX6C antibodies in Western blot?

Non-specific binding is a common challenge when using COX6C antibodies in Western blot applications. To troubleshoot this issue, researchers can implement the following methodological approaches:

• Optimize antibody concentration: Titrate antibody dilutions (e.g., 1:500, 1:750, 1:1000) to identify the optimal concentration that provides specific signal with minimal background .

• Adjust blocking conditions: Increase blocking time or modify blocking reagent composition. For COX6C antibodies, 5% non-fat dry milk or 3-5% BSA in TBST are commonly effective.

• Increase washing stringency: Additional or longer washing steps with TBST (Tris-buffered saline with 0.1% Tween-20) can reduce non-specific signals.

• Use positive and negative controls:

  • Positive control: Human heart tissue lysate is known to express COX6C

  • Negative control: Samples from COX6C knockout cells or tissues, or samples with COX6C knockdown

• Verify molecular weight: Confirm that detected bands align with the expected molecular weight of 9 kDa for COX6C . Divergent bands at significantly different sizes may represent non-specific binding or post-translational modifications.

• Consider sample preparation: Ensure complete protein denaturation and proper reduction of disulfide bonds. For mitochondrial proteins like COX6C, specialized extraction protocols may yield better results.

• Validate with alternate antibodies: If possible, confirm results using different COX6C antibodies targeting distinct epitopes to rule out antibody-specific artifacts.

By systematically implementing these approaches, researchers can significantly improve the specificity of COX6C detection in Western blot experiments.

What are the recommended controls for validating COX6C antibody specificity?

To rigorously validate COX6C antibody specificity, researchers should implement multiple control strategies:

• Positive expression controls:

  • Human heart tissue, which has documented COX6C expression

  • Cell lines with known high COX6C expression (e.g., HepG2 cells)

  • Recombinant COX6C protein or overexpression systems

• Negative controls:

  • COX6C knockout or knockdown samples: RNA interference or CRISPR-based methods to reduce COX6C expression

  • Tissues or cells known to express minimal COX6C

  • Primary antibody omission controls in immunostaining

• Peptide competition assays:

  • Pre-incubate the COX6C antibody with the immunizing peptide (for antibodies raised against synthetic peptides)

  • Signal elimination or reduction confirms binding specificity

• Cross-validation with multiple detection methods:

  • Confirm protein expression using orthogonal techniques (e.g., mass spectrometry)

  • Compare results from multiple antibodies targeting different epitopes of COX6C

  • Correlate protein detection with mRNA expression data

• Species reactivity validation:

  • Confirm antibody performance across claimed species reactivity (human, mouse, rat)

  • Use appropriate positive controls for each species

• Application-specific controls:

  • For IHC: Include normal adjacent tissue as internal control

  • For IF: Include subcellular localization controls (mitochondrial markers)

  • For WB: Include molecular weight markers and loading controls

Proper validation not only ensures experimental rigor but also enhances reproducibility and reliability of research findings involving COX6C.

How can COX6C antibodies be used to investigate mitochondrial assembly and function?

COX6C antibodies can be powerful tools for investigating mitochondrial assembly and function through several sophisticated experimental approaches:

• Analysis of Cytochrome c Oxidase Assembly Intermediates:

  • COX6C antibodies can be used in immunoprecipitation experiments to isolate and characterize assembly intermediates of cytochrome c oxidase

  • When combined with pulse-chase labeling techniques, researchers can track the incorporation of COX6C into the enzyme complex over time

  • This approach has revealed that COX6C is a component of the Cox1 assembly module, providing insights into the step-wise assembly process of COX

• Investigation of Mitochondrial Supercomplexes:

  • Blue Native PAGE (BN-PAGE) combined with COX6C immunoblotting allows visualization of respiratory chain supercomplexes

  • This technique can reveal how mutations or environmental factors affect the integration of COX into higher-order structures

  • Studies have shown that altered COX6C expression can impact the formation of supercomplexes, affecting respiratory efficiency

• Mitochondrial Proteomics and Interactome Analysis:

  • COX6C antibodies enable the identification of novel protein-protein interactions through techniques like proximity labeling or co-immunoprecipitation

  • Research has identified interactions between COX6C and Atp9 (a component of ATP synthase) in complexes called Atco, which function in the biogenesis of both cytochrome oxidase and ATP synthase

• Functional Consequences of COX6C Alterations:

  • Knockdown studies combined with COX6C antibody-based detection can reveal how changes in COX6C levels affect mitochondrial morphology, membrane potential, and respiratory capacity

  • Such approaches have demonstrated that COX6C knockdown can lead to increased cellular rounding and mitotic defects

These methodologies provide researchers with powerful means to unravel the complex roles of COX6C in mitochondrial biogenesis, assembly, and function.

What insights have been gained about COX6C's role in cancer through antibody-based studies?

Antibody-based studies have provided significant insights into COX6C's emerging role in cancer biology:

• Altered Expression in Multiple Cancer Types:

  • Immunohistochemical analysis using COX6C antibodies has revealed upregulation in several cancer types, including lung adenocarcinoma (LUAD) and prostate cancer

  • Western blot analysis has confirmed increased COX6C protein levels in tumor tissues compared to adjacent normal tissues

• Genomic Amplification Driving COX6C Overexpression:

  • Studies combining COX6C antibody-based protein detection with genomic analyses have demonstrated that COX6C expression can be driven by copy number amplification of chromosome 8q22.2

  • This finding establishes a direct link between genomic alterations and functional consequences at the protein level

• Functional Impact on Cancer Cell Phenotypes:

  • Knockdown of COX6C in cancer cell lines (e.g., H1975 lung cancer cells) followed by antibody-based detection has revealed that COX6C reduction leads to distinct cellular phenotypes :

    • Increased frequency of round cells

    • Mitotic defects

    • Altered cell cycle progression

• Tissue Microarray (TMA) Studies:

  • Large-scale immunohistochemical analyses using COX6C antibodies on tissue microarrays containing paired tumor and normal tissues from 145 LUAD patients have provided crucial data on expression patterns and clinical correlations

  • Such studies help establish the potential diagnostic and prognostic value of COX6C in cancer

• Potential Therapeutic Implications:

  • By utilizing COX6C antibodies to monitor protein levels, researchers can assess the effects of various therapeutic interventions that target mitochondrial function in cancer cells

  • This approach helps identify tumors that might be particularly vulnerable to metabolism-targeting therapies

These findings collectively suggest that COX6C may play more complex roles beyond its canonical function in oxidative phosphorylation, potentially contributing to cancer development and progression.

How can researchers interpret discrepancies in COX6C molecular weight detection between different studies?

Researchers occasionally encounter discrepancies in the detected molecular weight of COX6C, which can cause confusion and interpretive challenges. The observed molecular weight can vary from the expected 9 kDa to approximately 32 kDa in different studies. These discrepancies can be methodically analyzed using the following framework:

• Protein Characteristics and Post-translational Modifications:

  • While the calculated molecular weight of COX6C is 9 kDa (75 amino acids) , post-translational modifications can significantly alter migration patterns

  • Phosphorylation, glycosylation, ubiquitination, or SUMOylation may explain higher molecular weight observations

  • Researchers should consider using phosphatase treatment or other modification-specific enzymes to evaluate this possibility

• Antibody Epitope Considerations:

  • Different antibodies target distinct epitopes of COX6C:

    • The 11429-2-AP antibody was generated against a COX6C fusion protein (Ag1982)

    • The YP-mAb-02548 was produced against a synthesized peptide derived from human COX6C (AA range: 11-60)

  • Epitope location can affect detection of different isoforms or modified variants

• Sample Preparation Influences:

  • Protein extraction methods significantly impact observed molecular weights:

    • Harsh detergents may dissociate protein complexes

    • Different extraction buffers may preserve or disrupt post-translational modifications

  • For mitochondrial proteins like COX6C, specialized extraction methods may yield different results

• Technical Considerations:

  • Gel percentage and running conditions affect migration patterns

  • Gel systems (Tris-glycine vs. Tris-tricine) have different resolving capabilities for low molecular weight proteins

  • Calibration standards and reference proteins influence apparent molecular weight calculations

• Biological Variables:

  • Different cell/tissue types may express distinct COX6C isoforms

  • Disease states (e.g., cancer) may alter COX6C processing or modification

  • In mitochondrial studies, the observed 32 kDa band might represent COX6C in a stable complex with interacting partners

When encountering such discrepancies, researchers should:

• Report all observed bands with their molecular weights

• Validate findings with multiple antibodies targeting different epitopes

• Use mass spectrometry for definitive protein identification

• Consider performing 2D gel electrophoresis to separate proteins by both isoelectric point and molecular weight

These comprehensive approaches help resolve ambiguities and enhance the reliability of COX6C detection in experimental settings.

What methodologies are available for studying the interaction between COX6C and Atp9 in Atco complexes?

Research has identified important interactions between COX6C and Atp9 (a component of ATP synthase) in complexes called Atco, which function in the biogenesis of both cytochrome oxidase and ATP synthase. Several sophisticated methodologies are available for investigating these interactions:

• In Organello Radiolabeling for Assembly Kinetics:

  • Pulse-labeling mitochondria with 35S-methionine/cysteine enables tracking of newly synthesized COX6C

  • This approach revealed that only a fraction of newly translated Cox6 is present in Atco complexes

  • The technique provides temporal resolution of complex assembly not achievable with steady-state measurements

• Allotopic Expression Systems:

  • Relocation of COX6C from the nuclear to the mitochondrial genome (as demonstrated with the COX6-C construct) offers a unique system to study assembly dynamics

  • This experimental system revealed that mitochondrially encoded COX6C can still form complexes with Atp9, confirming the fundamental nature of this interaction regardless of the source of COX6C

• Affinity Purification Coupled with Mass Spectrometry:

  • Protein C-tagged COX6C can be purified using protein C antibody beads

  • This approach successfully co-purified Atp9 with COX6C, confirming their association

  • Subsequent mass spectrometry analysis can identify additional components of these complexes

• Blue Native PAGE for Intact Complex Analysis:

  • BN-PAGE combined with Western blotting allows visualization of native Atco complexes

  • This technique revealed that alterations in COX6C expression affect the levels of respiratory supercomplexes

  • Different detergents (typically 2% digitonin) can be used to extract and preserve these complexes

• Genetic Approaches to Investigate Functional Significance:

  • Comparative analysis of wild-type and COX6C mutant strains allows assessment of the physiological importance of these interactions

  • Complementation studies with relocalized COX6C genes have demonstrated that Atco is an obligatory source of Cox6 for COX biogenesis

These methodologies collectively provide powerful means to dissect the stoichiometry, dynamics, and functional significance of COX6C-Atp9 interactions in mitochondrial biogenesis.

How can researchers investigate the impact of COX6C copy number amplification on protein expression in cancer?

The relationship between COX6C copy number amplification (particularly at chromosome 8q22.2) and protein expression in cancer represents an important research area. Several methodological approaches can be employed to investigate this relationship:

• Integrated Genomic and Proteomic Analysis:

  • Copy number verification using MALDI-TOF MS to analyze SNP sites with high allele frequency

  • Calculation of allelic ratios to determine copy number status

  • Correlation with protein expression levels determined by COX6C antibody-based Western blotting

• Tissue Microarray (TMA) Analysis:

  • Construction of TMAs containing paired tumor and normal tissues from cancer patients (e.g., 145 LUAD cases)

  • Immunohistochemical staining with COX6C antibodies

  • Quantitative scoring of staining intensity

  • Correlation with genomic copy number data from the same patients

• Functional Validation Through Genetic Manipulation:

  • CRISPR-based approaches to create isogenic cell lines with different COX6C copy numbers

  • shRNA knockdown or overexpression systems to modulate COX6C levels

  • Western blot and functional assays to assess consequences of altered expression

• Multi-level Expression Analysis:

  • qRT-PCR for mRNA quantification

  • Western blotting for protein levels

  • Assessment of whether genomic amplification translates to proportional increases at mRNA and protein levels

• Clinical Correlation Studies:

  • Analysis of patient survival data in relation to both COX6C copy number and protein expression

  • Investigation of associations with clinical parameters (tumor stage, grade, treatment response)

  • Multivariate analyses to determine independent prognostic value

• Mechanistic Studies on Amplification-Driven Phenotypes:

  • Investigation of how COX6C overexpression affects cancer cell phenotypes (e.g., increased round cells and mitotic defects observed in H1975 cells)

  • Exploration of whether inhibition of COX6C in amplified tumors provides therapeutic opportunities

These approaches provide a comprehensive framework for understanding how genomic alterations in COX6C translate to functional consequences at the protein level and ultimately affect cancer biology.

What are the current technical challenges in detecting COX6C in different cellular compartments using immunofluorescence?

Detecting COX6C in different cellular compartments using immunofluorescence (IF) presents several technical challenges that researchers must address for accurate localization studies:

• Preserving Mitochondrial Morphology and Epitope Accessibility:

  • COX6C is located in the mitochondrial inner membrane , making epitope accessibility challenging

  • Fixation methods critically impact mitochondrial morphology and antibody penetration:

    • Paraformaldehyde (4%) preserves structure but may reduce epitope accessibility

    • Methanol fixation improves permeabilization but can distort mitochondrial morphology

    • Combined protocols with brief PFA fixation followed by methanol permeabilization often yield optimal results

• Signal-to-Noise Ratio Optimization:

  • The relatively low abundance of COX6C requires careful optimization of antibody dilutions (typically 1:200-1:1000)

  • Background fluorescence from non-specific binding necessitates extensive blocking:

    • Extended blocking periods (1-2 hours) with 5-10% normal serum

    • Addition of 0.1-0.3% Triton X-100 for improved permeabilization

    • BSA (3-5%) to reduce non-specific antibody binding

• Multi-label Strategies for Accurate Localization:

  • Co-staining with established mitochondrial markers is essential:

    • MitoTracker dyes for live-cell mitochondrial labeling

    • Tom20 or VDAC antibodies for mitochondrial outer membrane

    • Prohibitin or Tim23 for inner membrane markers

  • Careful selection of secondary antibodies to avoid spectral overlap

• Distinguishing Functional Pools of COX6C:

  • COX6C exists in multiple functional states (free protein, Atco complexes, and mature COX)

  • Standard IF cannot readily distinguish between these pools

  • Advanced techniques required:

    • Proximity ligation assay (PLA) to detect specific interactions

    • FRET-based approaches for protein proximity detection

    • Super-resolution microscopy to resolve suborganellar locations

• Technical Considerations for Imaging:

  • The small size of mitochondria (typically 0.5-1μm in diameter) necessitates high-resolution imaging

  • Deconvolution or super-resolution techniques (STED, STORM, PALM) significantly improve visualization

  • Z-stack acquisition essential for accurate 3D localization

  • Quantitative image analysis algorithms needed for objective assessment

• Validation Strategies:

  • Controls for antibody specificity (peptide competition, COX6C knockdown cells)

  • Subcellular fractionation with Western blot validation

  • Correlation with functional assays (respiratory capacity measurements)

Addressing these challenges systematically enables more reliable detection and localization of COX6C, advancing our understanding of its roles in different cellular compartments and conditions.

How might single-cell analysis techniques be applied to study COX6C heterogeneity in tissues?

Emerging single-cell technologies offer unprecedented opportunities to investigate COX6C heterogeneity across individual cells within complex tissues, potentially revealing functional diversity not apparent in bulk analyses:

• Single-Cell Immunofluorescence Technologies:

  • Multiplex immunofluorescence combined with COX6C antibodies enables visualization of expression heterogeneity while preserving spatial context

  • Imaging mass cytometry (IMC) allows simultaneous detection of multiple proteins including COX6C at single-cell resolution

  • Spatial transcriptomics coupled with protein detection can correlate COX6C protein levels with gene expression patterns in situ

• Flow Cytometry and Mass Cytometry Applications:

  • Intracellular staining protocols optimized for COX6C detection enable quantification across large cell populations

  • Mass cytometry (CyTOF) allows measurement of COX6C alongside dozens of other markers without spectral overlap concerns

  • Cell sorting based on COX6C levels followed by functional assays can reveal phenotypic consequences of expression variability

• Single-Cell Proteomics Approaches:

  • Recent advances in single-cell proteomics make it feasible to quantify COX6C at the individual cell level

  • Integration with mitochondrial functional parameters can reveal correlations between COX6C levels and respiratory capacity

  • Development of nanobody-based detection systems may improve sensitivity for low-abundance mitochondrial proteins like COX6C

• Computational Analysis of Heterogeneity:

  • Machine learning algorithms can identify distinct cell subpopulations based on COX6C expression patterns

  • Trajectory inference methods may reveal dynamic changes in COX6C expression during cellular processes

  • Network analysis can position COX6C within cell-type-specific protein interaction networks

• Clinical and Translational Applications:

  • Analysis of COX6C heterogeneity in patient samples may reveal clinically relevant subpopulations

  • In cancer tissues, spatial mapping of cells with chromosomal 8q22.2 amplification and corresponding COX6C protein levels could identify tumor regions with distinct metabolic properties

  • Single-cell multiomics approaches integrating genomic, transcriptomic, and proteomic data may uncover regulatory mechanisms driving COX6C heterogeneity

These emerging technologies promise to transform our understanding of COX6C biology by revealing cell-to-cell variability that may have important functional and clinical implications.

What are the prospects for developing therapeutic strategies targeting COX6C in cancer?

The emerging role of COX6C in cancer biology, particularly its amplification in lung adenocarcinoma and other cancers , presents several avenues for therapeutic development. Future research directions may include:

• Direct Inhibition Strategies:

  • Development of small molecule inhibitors specifically targeting COX6C

  • Peptide-based approaches to disrupt COX6C interactions with other components of the respiratory chain

  • Evaluation of natural compounds that selectively modulate COX6C function

• Exploiting Metabolic Vulnerabilities:

  • Cancer cells with COX6C amplification may exhibit altered metabolic dependencies

  • Synthetic lethality approaches combining COX6C targeting with inhibitors of compensatory metabolic pathways

  • Metabolic profiling to identify unique vulnerabilities in tumors with high COX6C expression

• Genomic and Epigenetic Targeting:

  • CRISPR-based approaches to specifically target amplified COX6C loci

  • Epigenetic modifiers to regulate COX6C expression

  • Antisense oligonucleotides or siRNA-based therapeutics to reduce COX6C levels

• Immunotherapeutic Approaches:

  • Exploration of COX6C as a potential tumor-associated antigen for immunotherapy

  • Development of antibody-drug conjugates targeting surface-exposed mitochondrial proteins in cancer cells with altered mitochondrial dynamics

  • Evaluation of whether metabolic alterations associated with COX6C amplification affect tumor immunogenicity

• Combination Therapy Strategies:

  • Identification of synergistic combinations of COX6C-targeted therapies with conventional chemotherapeutics

  • Investigation of whether COX6C inhibition sensitizes tumors to radiation therapy

  • Exploration of combinations with other mitochondria-targeting agents

• Biomarker Development:

  • Validation of COX6C amplification or protein overexpression as predictive biomarkers for response to metabolism-targeting therapies

  • Development of companion diagnostics using COX6C antibodies for patient stratification

  • Longitudinal assessment of COX6C as a marker of treatment response

These research directions highlight the potential therapeutic significance of COX6C in cancer treatment, particularly for tumors characterized by 8q22.2 amplification. The development of COX6C antibodies with improved specificity will be crucial for advancing these therapeutic strategies and companion diagnostics.

How might advances in cryo-electron microscopy contribute to understanding COX6C structure-function relationships?

Recent advances in cryo-electron microscopy (cryo-EM) offer transformative opportunities for elucidating COX6C structure-function relationships at unprecedented resolution, potentially revolutionizing our understanding of this protein's role in mitochondrial function and disease:

• High-Resolution Structural Analysis:

  • Cryo-EM can now achieve near-atomic resolution of membrane protein complexes like cytochrome c oxidase

  • This enables precise mapping of COX6C's position within the holoenzyme

  • Structural information can reveal how COX6C contributes to enzyme stability, assembly, and function

• Visualization of Dynamic Assembly Intermediates:

  • Time-resolved cryo-EM approaches can capture various assembly states of cytochrome c oxidase

  • This could reveal the temporal sequence of COX6C incorporation during complex formation

  • Visualization of Atco complexes containing both COX6C and Atp9 would provide crucial insights into their structural relationship

• Conformational Dynamics and Functional States:

  • Modern cryo-EM methods can resolve multiple conformational states within a single sample

  • This capability could reveal how COX6C participates in conformational changes during electron transfer

  • Computational approaches like 3D variability analysis can map the conformational landscape of cytochrome c oxidase

• Structure-Guided Antibody Development:

  • High-resolution structures enable epitope mapping of existing COX6C antibodies

  • This information can guide the development of next-generation antibodies with improved specificity

  • Structure-based design of conformation-specific antibodies could distinguish between different functional states of COX6C

• Pathogenic Variant Analysis:

  • Cryo-EM structures can provide a framework for interpreting the impact of disease-associated variants

  • Mutations affecting COX6C structure, stability, or interactions can be modeled based on high-resolution data

  • This structural context is essential for understanding how genetic alterations impact protein function

• Drug Discovery Applications:

  • Atomic-resolution structures enable structure-based drug design targeting COX6C or its interactions

  • Virtual screening against structural pockets can identify small molecules that modulate COX6C function

  • Fragment-based approaches guided by structural data could lead to novel therapeutic candidates

• In Situ Structural Biology:

  • Cryo-electron tomography (cryo-ET) allows visualization of macromolecular complexes in their native cellular environment

  • This approach could reveal how COX6C-containing complexes are organized within the mitochondrial inner membrane

  • Correlative light and electron microscopy (CLEM) combined with COX6C antibodies can provide functional context to structural data

These advanced structural biology approaches promise to bridge the gap between molecular structure and biological function, potentially leading to new therapeutic strategies targeting COX6C in various disease contexts.